Biogen Inc. (Nasdaq: BIIB) announced it will present data from its movement disorders portfolio at the upcoming International Congress of Parkinson’sDisease and Movement Disorders (MDS) in Hong Kong (Oct. 5-9, 2018).
Data being presented are from Biogen’s research programs evaluating potential treatments for progressive supranuclear palsy (PSP) and Parkinson’s disease (PD) as part of its larger neurology pipeline.
‘The data being presented at MDS are a testament to Biogen’s commitment to its goal of delivering innovative therapies for people living with complex, neurodegenerative conditions like PSP and PD,’ said Kate Dawson, M.D., vice president of late-stage clinical development at Biogen. ‘PSP and PD both have significant unmet need, especially for disease modifying therapies, so we look forward to advancing the clinical development programs to help better understand these challenging conditions.’
Biogen PSP presentations will focus on safety data from the Phase 1 long-term extension study and baseline demographics from the Phase 2 PASSPORT study. The company’s BIIB092 program has recently met milestones, including recruitment completion for the Phase 2 PASSPORT study and fast track designation by the U.S. Food and Drug Administration for PSP. PSP is a rare neurodegenerative disease, considered to be a primary tauopathy, characterized by rapidly progressing physical impairments, such as difficulty speaking, swallowing and walking, as well as cognitive/behavioral impairments, such as apathy and dementia.
PD presentations will feature an overview of the design of the BIIB054 SPARK Phase 2 study, which is the most advanced program in Biogen’s PD pipeline. PD is the second most common neurodegenerative disease after Alzheimer’s disease. Motor symptoms of PD include bradykinesia, muscular rigidity, rest tremor and postural and gait impairment.1
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.